Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07274449 | Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors(NK) | active not recruiting | Phase 1 / Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 10, 2025 |
| clinicaltrials |
| NCT07274761 | Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. | active not recruiting | Phase 2 | 24 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05131919 | Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers(PUMA) | active not recruiting | Phase 2 | 25 | The Netherlands Cancer InstituteOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT06128863 | Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial(EFTISARC-NEO) | active not recruiting | Phase 2 | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06341114 | A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 112 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | active not recruiting | Phase 2 | 53 | Christian BuskeOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | active not recruiting | Phase 2 | 12 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07267286 | Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） | active not recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03212742 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients(OLA-TMZ-RTE-01) | active not recruiting | Phase 1 / Phase 2 | 91 | Centre Francois BaclesseOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03618537 | Ixazomib Maintenance Study in Patients With AL Amyloidosis | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05189457 | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | active not recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04963946 | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia(STAIR) | active not recruiting | Phase 2 | 160 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05867615 | Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:(LUBASKET) | active not recruiting | Phase 2 | 83 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05433116 | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | active not recruiting | Phase 2 | 50 | Universität des SaarlandesOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257575 | A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | active not recruiting | Phase 2 | 138 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05975307 | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) | active not recruiting | Phase 2 | 71 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06220318 | Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 155 | Fujian Haixi Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02570542 | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04940325 | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer(ICARUS-LUNG01) | active not recruiting | Phase 2 | 100 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03687957 | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide | active not recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05715281 | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | active not recruiting | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01697527 | Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 2 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02866136 | Conservative Treatments of Retinoblastoma(RETINO2011) | active not recruiting | Phase 2 | 133 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03718767 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | active not recruiting | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07127497 | Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02333435 | Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life(RCT-EPA) | active not recruiting | Phase 2 | 130 | CHU de Quebec-Universite LavalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT) | active not recruiting | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06345482 | A Study of MHB039A for Advanced Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 196 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06373406 | A Study of MHB036C for Advanced Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy(BladderSpar) | active not recruiting | Phase 2 | 79 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04070443 | Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase(TIPI) | active not recruiting | Phase 2 | 170 | Centre Leon BerardOTHER | 1 | Nov 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 10, 2025source: clinicaltrials